PRAECIS PHARMACEUTICALS INCORPORATED To Present at the Rodman & Renshaw Techvest 7th Annual Healthcare Conference on November 9,

PRAECIS PHARMACEUTICALS INCORPORATED (NASDAQ: PRCS),
today announced that Kevin F. McLaughlin, President and Chief
Executive Officer, and Richard W. Wagner, Ph.D., Executive Vice
President, Discovery Research, will present at the Rodman & Renshaw
Techvest 7th Annual Healthcare Conference in New York on November 9,
2005.

   The PRAECIS presentation may be accessed live beginning November
9, at 12:20 p.m., EST, at http://www.praecis.com under "Investors." A
copy of the presentation and a replay of the webcast will be available
on the Company's website beginning at 3:00 p.m., EST, until midnight
Friday, November 18.

   About PRAECIS

   PRAECIS PHARMACEUTICALS INCORPORATED is a biopharmaceutical
company focused on the discovery, development and commercialization of
innovative therapies that either address unmet medical needs or offer
improvements over existing therapies. PRAECIS has a novel MetAP-2
inhibitor, PPI-2458, in clinical development for non-Hodgkin's
lymphoma and solid tumors, as well as an innovative drug discovery
technology, Direct Select(TM), which enables the generation and
practical use of ultra-large libraries for the discovery of orally
active compounds for drug development. PRAECIS has received approval
to market Plenaxis(R) in both the United States and Germany.